Form 8-K - Current report:
SEC Accession No. 0001213900-24-089095
Filing Date
2024-10-21
Accepted
2024-10-21 08:00:22
Documents
14
Period of Report
2024-10-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0218096-8k_kyverna.htm   iXBRL 8-K 32099
2 PRESS RELEASE, DATED OCTOBER 21, 2024 ea021809601ex99-1_kyverna.htm EX-99.1 10513
  Complete submission text file 0001213900-24-089095.txt   223021

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kytx-20241020.xsd EX-101.SCH 3018
4 XBRL LABEL FILE kytx-20241020_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE kytx-20241020_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0218096-8k_kyverna_htm.xml XML 3679
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 241381979
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)